Literature DB >> 12832203

The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44.

Manfred Marschall1, Martina Freitag, Patricia Suchy, Daniel Romaker, Regina Kupfer, Miriam Hanke, Thomas Stamminger.   

Abstract

The protein kinase pUL97 of human cytomegalovirus plays important but incompletely defined roles in viral replication. Concerning the early phase of infection, it is postulated that pUL97 possesses regulatory functions in gene expression and/or DNA synthesis. Here we report that pUL97 interacts with an essential component of the replication complex, the DNA polymerase processivity factor pUL44. Interaction was determined by yeast two-hybrid and coimmunoprecipitation analyses and was mapped to the pUL97 region 366-459. In vitro kinase assays demonstrated that pUL44, coimmunoprecipitated either from transfected or from infected cells, is phosphorylated by pUL97 (but not by a catalytically inactive pUL97-mutant). In infected fibroblasts, immunofluorescence analysis revealed that pUL97 and pUL44 accumulate in the nucleus and are both incorporated into viral replication centers. The treatment with inhibitors of DNA synthesis or pUL97 kinase activity largely prevented colocalization. Thus, pUL97 may be indirectly involved in viral genome replication by modifying the replication cofactor pUL44.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12832203     DOI: 10.1016/s0042-6822(03)00147-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  51 in total

1.  Role of the specific interaction of UL112-113 p84 with UL44 DNA polymerase processivity factor in promoting DNA replication of human cytomegalovirus.

Authors:  Young-Eui Kim; Jin-Hyun Ahn
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.

Authors:  Sunwen Chou; Gail I Marousek; Anne E Senters; Michelle G Davis; Karen K Biron
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 3.  Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2012-04

Review 4.  Viral serine/threonine protein kinases.

Authors:  Thary Jacob; Céline Van den Broeke; Herman W Favoreel
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

Review 5.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.

Authors:  Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2008-11-03       Impact factor: 5.191

7.  Human cytomegalovirus UL97 kinase alters the accumulation of CDK1.

Authors:  Rachel B Gill; Scott H James; Mark N Prichard
Journal:  J Gen Virol       Date:  2012-05-02       Impact factor: 3.891

8.  Cyclin-dependent Kinases Phosphorylate the Cytomegalovirus RNA Export Protein pUL69 and Modulate Its Nuclear Localization and Activity.

Authors:  Sabine Rechter; Gillian M Scott; Jan Eickhoff; Katrin Zielke; Sabrina Auerochs; Regina Müller; Thomas Stamminger; William D Rawlinson; Manfred Marschall
Journal:  J Biol Chem       Date:  2009-01-29       Impact factor: 5.157

9.  Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.

Authors:  Rike Webel; Morgan Hakki; Mark N Prichard; William D Rawlinson; Manfred Marschall; Sunwen Chou
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

10.  Nucleolin associates with the human cytomegalovirus DNA polymerase accessory subunit UL44 and is necessary for efficient viral replication.

Authors:  Blair L Strang; Steeve Boulant; Donald M Coen
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.